Anjali Pandey
Plus aucun poste en cours
Profil
Anjali Pandey worked as a Vice President-Medicinal Chemistry at Portola Pharmaceuticals, Inc. from 2003 to 2018.
Prior to that, she worked as a Chemistry Director at COR Therapeutics, Inc. and Millennium Plc.
Dr. Pandey holds a doctorate degree from Southern Illinois University and a graduate degree from Indian Institute of Technology Kanpur.
Anciens postes connus de Anjali Pandey
| Sociétés | Poste | Fin |
|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2018 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - |
Millennium Plc
 Millennium Plc Miscellaneous Commercial ServicesCommercial Services Millennium Plc provides advertising and direct-marketing services. Its Clients include businesses in the financial services, publishing, and health care and consumer products industries. The company was founded in 1996 by Martin Smith and is headquartered in Shipley, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Anjali Pandey
| Southern Illinois University | Doctorate Degree |
| Indian Institute of Technology Kanpur | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Millennium Plc
Millennium Plc Miscellaneous Commercial ServicesCommercial Services Millennium Plc provides advertising and direct-marketing services. Its Clients include businesses in the financial services, publishing, and health care and consumer products industries. The company was founded in 1996 by Martin Smith and is headquartered in Shipley, the United Kingdom. | Commercial Services |